Thomas Ryckmans

Thomas Ryckmans has a diverse work experience in the pharmaceutical industry. Thomas is currently serving as the Director of Chemistry at Ridgeline Therapeutics since February 2020. Prior to that, they worked as a Co-leader and lecturer at Biozentrum, University of Basel starting from September 2016. From July 2017 to January 2020, Thomas held the role of Section Head, Medicinal Chemistry at Roche, where they supervised and developed a team of chemists and served as a medicinal chemistry liaison. Before joining Roche, they worked at Lundbeck as a Principal Scientist and at Pfizer as a Senior Principal Scientist and Senior Scientist. Thomas has also contributed to the field of medicinal chemistry as a part of the International Advisory Board at ChemMedChem. Thomas began their career at UCB Pharma as a Research Scientist/Medicinal Chemistry Project Manager.

Thomas Ryckmans has a Master's degree in Pharmacology from Université des Sciences et Technologies de Lille, which they obtained from 1999 to 2000. Prior to that, they completed a PhD in Synthetic Chemistry at Université catholique de Louvain from 1991 to 1995. In between, they pursued a post-doctoral degree in Asymmetric Catalysis at Nagoya University- Noyori Labs from 1995 to 1998.